Inside the Healthcare Market Research Revolution: A Conversation with Dr. Priya Anand
Introduction
The global healthcare market is one of the most consequential — and most methodologically challenging — arenas for market research. Valued at approximately $808 billion in 2023 and projected to grow at a CAGR of 5.4% through 2030 (Grand View Research), the sector is being reshaped simultaneously by digital health technology, post-pandemic care delivery transformation, pharmaceutical innovation, and mounting pressure on healthcare systems worldwide to demonstrate value-based outcomes.
To understand how market research practices are evolving in this complex environment, we spoke with Dr. Priya Anand, a healthcare market research strategist with over 15 years of experience advising pharmaceutical companies, medical device manufacturers, and digital health startups. Dr. Anand has led primary research programs across oncology, cardiovascular disease, and mental health verticals and currently serves as an advisory board member for the Healthcare Market Research Association (HMRA).
On the Changing Nature of Healthcare Research Briefs
You've described a shift in the types of questions healthcare clients are bringing to researchers. Can you explain what's changed?
Dr. Anand: Five years ago, a typical brief from a pharmaceutical client might ask us to assess physician prescribing intent for a new molecule, or to size the addressable patient population for a rare disease indication. Those are still important questions, but the nature of the brief has become substantially more complex. Today, we're routinely being asked to understand the entire care ecosystem — how a treatment decision involves not just the physician but the payer, the patient, the specialist, the pharmacist, and increasingly, an algorithm.
The rise of value-based care contracts means that pharmaceutical and device companies need to demonstrate clinical and economic outcomes to payers, not just to prescribers. That changes the research design fundamentally. You're not just doing physician surveys anymore — you're running health economics and outcomes research (HEOR) studies, real-world evidence generation programs, and payer advisory boards simultaneously.
"The research question used to be: 'Will doctors prescribe this drug?' Now it's: 'Under what conditions will payers reimburse it, and how do we build the evidence base to make that case?' That's a fundamentally different intellectual exercise." — Dr. Priya Anand
On Digital Health and New Data Sources
Digital health has generated enormous volumes of new data — wearables, electronic health records, patient apps. How is this reshaping primary research methodology?
Dr. Anand: It's creating both tremendous opportunity and real methodological tension. On the opportunity side, we now have access to behavioral health data — step counts, sleep patterns, medication adherence tracked through smart pill dispensers, glucose levels from continuous monitors — that gives us a far richer picture of patient experience than self-reported survey data ever could.
Companies like IQVIA and Symphony Health have built massive real-world data assets from claims and EHR data that can answer certain epidemiological questions with much greater precision than primary research. The IQVIA Human Data Science Cloud claims to contain data on over 1 billion non-identified patient records globally. That kind of scale changes what primary research needs to do — it's no longer about counting patients or estimating prevalence; it's about understanding the qualitative dimensions of lived experience that data exhaust can't capture.
The tension comes from data fragmentation and regulatory complexity. HIPAA in the US, GDPR in Europe, and an increasingly complex patchwork of national health data regulations mean that the most valuable data sets are often the hardest to access and link. I've seen research programs delayed by 12 to 18 months because of data governance issues that weren't anticipated in the project scoping phase.
How do you advise clients to navigate that regulatory complexity?
Dr. Anand: Engage your legal and compliance teams from day one — not as a downstream review function but as co-designers of the research protocol. For any study involving patient-level data, you need to understand the Institutional Review Board (IRB) or ethics committee requirements in every jurisdiction where you're operating. In the EU, research involving medical data also needs to comply with GDPR's specific provisions on health data processing under Article 9, which imposes requirements beyond standard data protection rules.
I'd also strongly recommend building relationships with patient advocacy organizations early in the research design process. Groups like the National Patient Advocate Foundation in the US or the European Patients Forum are increasingly sophisticated about research ethics and can serve as invaluable partners in designing studies that are both methodologically rigorous and respectful of patient communities.
On Physician Research in a Post-Pandemic World
Physician research has traditionally been a cornerstone of pharmaceutical market research. Has that changed post-pandemic?
Dr. Anand: Dramatically. Response rates for traditional physician surveys were already declining before COVID-19 — we were routinely seeing 15–20% response rates for online surveys by 2019, which creates real representativeness concerns. Post-pandemic, physician time pressure has intensified substantially, and the willingness to participate in lengthy research engagements has decreased further.
The industry has responded by moving toward shorter, more frequent touchpoints — micro-surveys of three to five questions embedded in medical education platforms or electronic prescribing systems — and by investing more heavily in physician panels maintained by specialist recruitment firms. The Medical Research Council's guidelines on minimizing research burden are worth studying here; they provide a framework for balancing research thoroughness with participant sustainability that more commercial research programs should adopt.
We're also seeing much greater investment in observational methodologies — ethnographic work in clinical settings, virtual shadowing of patient consultations with consent, and behavioral analysis of how physicians interact with digital clinical decision support tools. These approaches yield insights about actual clinical behavior that surveys of stated intent consistently fail to predict.
On AI in Healthcare Market Research
Artificial intelligence is being discussed everywhere in healthcare. What's your honest assessment of its current role in market research specifically?
Dr. Anand: I'll give you both the genuine promise and the appropriate skepticism. On the promising side, natural language processing applied to open-text survey responses, social media listening in patient communities, and medical literature is genuinely useful and increasingly mature. Tools like Brandwatch and Sprinklr, augmented with healthcare-specific ontologies, can surface patient sentiment and unmet need signals at scale that would have required months of qualitative fieldwork five years ago.
AI-assisted analysis of medical claims data to identify high-value patient segments and predict treatment pathway adherence is also showing real commercial value for pharmaceutical clients. Some research organizations are experimenting with AI-generated interview moderator scripts and adaptive survey designs that adjust question sequencing based on prior responses in real time.
The skepticism is warranted when AI is positioned as a substitute for human judgment in interpreting findings in a clinical context. Healthcare market research deals with life-and-death treatment decisions, reimbursement policies that affect patient access, and communication strategies that need to comply with stringent promotional guidelines from bodies like the FDA, EMA, and PMCDA. The consequences of a research error in this sector are qualitatively different from getting a consumer preference study wrong. AI tools should be treated as powerful analytical assistants, not as autonomous research agents.
Closing Thoughts: Advice for Emerging Healthcare Researchers
What's your single most important piece of advice for market researchers who want to build a career in healthcare?
Dr. Anand: Invest in understanding the clinical context deeply. The researchers who consistently produce the most valuable work in healthcare are those who have taken the time to genuinely understand how diseases are diagnosed and treated, how clinical trials work, how healthcare systems are structured in different countries, and how payment and reimbursement decisions are made. You don't need a medical degree — but you do need intellectual curiosity about medicine and healthcare systems that goes beyond what a client brief will tell you. Read clinical journals, attend medical conferences, spend time with patient communities. The research will be fundamentally better for it.
And embrace regulatory literacy. Knowing the difference between promotional and non-promotional research, understanding when an IRB approval is required, being familiar with PhRMA's code on interactions with healthcare professionals — these aren't just compliance checkboxes. They're the guardrails that protect research integrity in a sector where the stakes are extraordinarily high.